HSBC Holdings’s iTeos Therapeutics ITOS Stock Holding History

HSBC Holdings’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-68,533	Closed	-$686K	–	2925
2025 Q2	$686K	Sell	68,533 -8,460	-11%	-$68.2K	﹤0.01%	1989
2025 Q1	$458K	Buy	76,993 +29,587	+62%	+$217K	﹤0.01%	2128
2024 Q4	$355K	Buy	47,406 +14,288	+43%	+$123K	﹤0.01%	2392
2024 Q3	$335K	Buy	33,118 +20,541	+163%	+$313K	﹤0.01%	2262
2024 Q2	$190K	Sell	12,577 -29,986	-70%	-$430K	﹤0.01%	2573
2024 Q1	$581K	Sell	42,563 -13,393	-24%	-$146K	﹤0.01%	2030
2023 Q4	$611K	Buy	55,956 +42,886	+328%	+$425K	﹤0.01%	1968
2023 Q3	$143K	Buy	+13,070	New	+$167K	﹤0.01%	2491

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HSBC Holdings's ITOS Position: Q3 2025 in Review

HSBC Holdings sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 68,533 shares — an estimated $686K sold.

HSBC Holdings first reported a position in ITOS in Q3 2023 and held it in 8 quarters. The position peaked at $686K in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

HSBC Holdings reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
HSBC Holdings sold 68,533 iTeos Therapeutics shares in Q3 2025, an estimated $686K.
HSBC Holdings first reported a position in iTeos Therapeutics in Q3 2023 and held it in 8 quarters.
HSBC Holdings's iTeos Therapeutics position peaked at $686K in Q2 2025.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.